



00 · EXECUTIVE BRIEF

AI clinical intelligence for *elite & longevity medicine.*

CLINIOS ONE PREMIUM · PRE-SEED 2026 · NON-SAMD · DATA IN EUROPE (GDPR)

LONGEV'AI builds the clinical operating systems of health and longevity — **AI in the service of physicians and patients.** Its flagship, CLINIOS One Premium, is the first clinical OS conceived for the elite, multicultural clinic of the Gulf and the Mediterranean.

\$47BADDRESSABLE MARKET ·
5,200 ELITE CLINICS**€112k**ARR PER CLINIC ·
FOUNDING COHORT**24**FOUNDING-COHORT CLINICS
· RESERVATION BY 30 NOV
2026**Pre-seed**CURRENT ROUND · PATH TO
SERIES A

01 THE OPPORTUNITY

Elite and longevity clinics — premium aesthetics, regenerative & preventive longevity medicine, UHNW clinical longevity, and medicalised spa & wellness — are scaling fast while running on fragmented, generic software built for mass-market practices. LONGEV'AI closes that gap with a single clinical operating system that orchestrates the entire experience of an elite clinic: patient memory, family coordination, multilingual cultural excellence, and physician-grade clinical intelligence.

02 THE PRODUCT

CLINIOS One Premium is a clinical operating system delivered as software for the clinic — deliberately **non-SaMD** in its current scope, which avoids the European Class IIa medical-device pathway and compresses time-to-market. Data is hosted in Europe on a dedicated private, sovereign cloud, fully GDPR-compliant. The platform is built around an **EN·FR·AR native** core scaling by signed territory, with a dedicated **Cultural Excellence** module engineered for the codes of the Gulf.

03 THE BUSINESS MODEL

A deliberately scarce **founding cohort of 24 clinics** (6 Founders + 18 Charter) at **€112,000 / year**, secured with a **€41,630 refundable deposit** held until activation. Reservation closes **30 November 2026**; post-Charter pricing rises to **€162,500 / year**. Distribution is amplified by a performance-based business-introducer network already deployed across Switzerland, the Gulf, North Africa and Asia.

04 WHERE WE ARE

Paris-based, founded in 2026. The brand, the CLINIOS One Premium prototype and the introducer network are live; **two elite clinics are in active discussion.** The company is now incorporating its operating company (SAS) and raising a pre-seed round to convert this momentum into signed, paying founding-cohort clinics.

05 THE TEAM



Sarra Abada — Founder & CEO. Medically trained, with hospital residencies in internal medicine and psychiatry. Conceived CLINIOS as the clinical OS the elite, multicultural clinic was missing — and has built the brand, prototype and introducer network to date.

Supported by a lead developer on product and engineering. The pre-seed round funds the first key hires across clinical product, go-to-market and engineering.

06 THE RAISE

LONGEV'AI is raising a **pre-seed round** to incorporate the SAS, finish the product, and sign the first founding-cohort clinics — with a clear path to a Series A once traction lands. Indicative use of proceeds: product & technology (35%), go-to-market & founding cohort (30%), team (25%), legal & runway (10%). Strategic horizon: **Sanabil × Vision 2030** — entering via the early-stage accelerator track and scaling toward an institutional Series A. See the Investment Thesis and Roadmap.

CONFIDENTIAL · LONGEV'AI CLINICAL INTELLIGENCE · PARIS · 2026 · NOT FOR DISTRIBUTION